PAX3-FOXO1 Fusion Gene in Rhabdomyosarcoma

Overview

Journal Cancer Lett

Specialty Oncology

Date 2008 May 7

PMID 18457914

Citations 74

Authors

Corinne M Linardic

Affiliations

Soon will be listed here.

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. The predominant histologic variants of this disease are termed embryonal (eRMS) and alveolar (aRMS), based on their appearance under light microscopy. Of the two, aRMS is associated with an more aggressive disease pattern and a higher mortality, mandating a better understanding of this cancer at the molecular level. The PAX3-FOXO1 fusion gene, resulting from the stable reciprocal translocation of chromosomes 2 and 13, is a signature genetic change found only in aRMS, and thought to be responsible at least in part for its malignant phenotype. This review will discuss the clinical significance of the PAX3-FOXO1 fusion gene, the pertinent historical and current models used to study its oncogenic contributions, the transcriptional targets that are thought to mediate these contributions, and the cellular mechanisms impacted by PAX3-FOXO1 that ultimately lead to aRMS.

Citing Articles

Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.

Sias F, Zoroddu S, Migheli R, Bagella L Int J Mol Sci. 2025; 26(5).

PMID: 40076599 PMC: 11900228. DOI: 10.3390/ijms26051973.

Molecular principles underlying aggressive cancers.

Nussinov R, Yavuz B, Jang H Signal Transduct Target Ther. 2025; 10(1):42.

PMID: 39956859 PMC: 11830828. DOI: 10.1038/s41392-025-02129-7.

FusOn-pLM: a fusion oncoprotein-specific language model via adjusted rate masking.

Vincoff S, Goel S, Kholina K, Pulugurta R, Vure P, Chatterjee P Nat Commun. 2025; 16(1):1436.

PMID: 39920196 PMC: 11806025. DOI: 10.1038/s41467-025-56745-6.

Myogenesis gone awry: the role of developmental pathways in rhabdomyosarcoma.

Gustafson A, Durbin A, Artinger K, Ford H Front Cell Dev Biol. 2025; 12:1521523.

PMID: 39902277 PMC: 11788348. DOI: 10.3389/fcell.2024.1521523.

Pediatric head and neck sarcomas: a retrospective study from a national tertiary referral center.

Bandora E, Kampel L, Manisterski M, Elhasid R, Levin D, Horowitz G Eur J Pediatr. 2025; 184(2):169.

PMID: 39893262 DOI: 10.1007/s00431-025-05991-3.

References

Barr F . The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma. Cancer Res. 1999; 59(7 Suppl):1711s-1715s. View

Collins M, Zhao H, Womer R, Barr F . Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions. Med Pediatr Oncol. 2001; 37(2):83-9. DOI: 10.1002/mpo.1174. View

Galili N, Davis R, Fredericks W, Mukhopadhyay S, Rauscher 3rd F, Emanuel B . Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 5(3):230-5. DOI: 10.1038/ng1193-230. View

Schaaf G, Ruijter J, van Ruissen F, Zwijnenburg D, Waaijer R, Valentijn L . Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries. FASEB J. 2005; 19(3):404-6. DOI: 10.1096/fj.04-2104fje. View

Linardic C, Naini S, Herndon 2nd J, Kesserwan C, Qualman S, Counter C . The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res. 2007; 67(14):6691-9. DOI: 10.1158/0008-5472.CAN-06-3210. View

Hadnagy A, Gaboury L, Beaulieu R, Balicki D . SP analysis may be used to identify cancer stem cell populations. Exp Cell Res. 2006; 312(19):3701-10. DOI: 10.1016/j.yexcr.2006.08.030. View

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude G . Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4(12):915-25. DOI: 10.1038/nrm1261. View

Davicioni E, Graf Finckenstein F, Shahbazian V, Buckley J, Triche T, Anderson M . Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 2006; 66(14):6936-46. DOI: 10.1158/0008-5472.CAN-05-4578. View

Pinto A, Tallini G, Novak R, Bowen T, Parham D . Undifferentiated rhabdomyosarcoma with lymphoid phenotype expression. Med Pediatr Oncol. 1997; 28(3):165-70. DOI: 10.1002/(sici)1096-911x(199703)28:3<165::aid-mpo1>3.0.co;2-h. View

10.

Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A . Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?. Br J Cancer. 2001; 85(6):831-5. PMC: 2375077. DOI: 10.1054/bjoc.2001.2008. View

11.

Khan J, Simon R, Bittner M, Chen Y, Leighton S, Pohida T . Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res. 1998; 58(22):5009-13. View

12.

Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y . Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun. 2007; 365(3):568-74. DOI: 10.1016/j.bbrc.2007.11.017. View

13.

del Peso L, Gonzalez V, Hernandez R, Barr F, Nunez G . Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene. 1999; 18(51):7328-33. DOI: 10.1038/sj.onc.1203159. View

14.

Khan J, Wei J, Ringner M, Saal L, Ladanyi M, Westermann F . Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med. 2001; 7(6):673-9. PMC: 1282521. DOI: 10.1038/89044. View

15.

Onisto M, Slongo M, Gregnanin L, Gastaldi T, Carli M, Rosolen A . Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol. 2005; 27(3):791-8. View

16.

Libura J, Drukala J, Majka M, Tomescu O, Navenot J, Kucia M . CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood. 2002; 100(7):2597-606. DOI: 10.1182/blood-2002-01-0031. View

17.

Davis R, Barr F . Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A. 1997; 94(15):8047-51. PMC: 21554. DOI: 10.1073/pnas.94.15.8047. View

18.

Leshem Y, Gitelman I, Ponzetto C, Halevy O . Preferential binding of Grb2 or phosphatidylinositol 3-kinase to the met receptor has opposite effects on HGF-induced myoblast proliferation. Exp Cell Res. 2002; 274(2):288-98. DOI: 10.1006/excr.2002.5473. View

19.

Ferracini R, Olivero M, Di Renzo M, Martano M, De Giovanni C, Nanni P . Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene. 1996; 12(8):1697-705. View

20.

Zhang L, Wang C . PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27Kip1, a potential role for elevated Skp2 expression. J Biol Chem. 2002; 278(1):27-36. DOI: 10.1074/jbc.M205424200. View